Literature DB >> 6425455

L-deprenyl plus L-phenylalanine in the treatment of depression.

W Birkmayer, P Riederer, W Linauer, J Knoll.   

Abstract

The antidepressive efficacy of 1-deprenyl (5-10 mg daily) plus 1-phenylalanine (250 mg/day) has been evaluated in 155 unipolar depressed patients. Both oral and intravenous administration showed beneficial effects in 90% of outpatients and 80.5% of inpatients. It is concluded that this combined treatment has a potent antidepressive action based on the accumulation of 1-phenylethylamine in the brain.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6425455     DOI： 10.1007/bf01249880

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  18 in total

1.  HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS.

Authors:  B BLACKWELL
Journal:  Lancet       Date:  1963-10-26       Impact factor: 79.321

2.  [Experimental findings and new aspects in extrapyramidal diseases].

Authors:  W Birkmayer
Journal:  Wien Z Nervenheilkd Grenzgeb       Date:  1966

3.  Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1973-11       Impact factor: 4.030

4.  [Deficit of essential amino acids in endogenous depression].

Authors:  W Birkmayer; E Neumayer; W Stöckl; G Weiler
Journal:  Wien Klin Wochenschr       Date:  1968-11-08       Impact factor: 1.704

5.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

6.  Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor.

Authors:  J Mendlewicz; M B Youdim
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

7.  Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.

Authors:  J D Elsworth; V Glover; G P Reynolds; M Sandler; A J Lees; P Phuapradit; K M Shaw; G M Stern; P Kumar
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

8.  Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").

Authors:  E Varga; L Tringer
Journal:  Acta Med Acad Sci Hung       Date:  1967

9.  Dl-phenylalanine in depressed patients: an open study.

Authors:  H Beckmann; M A Strauss; E Ludolph
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

10.  L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation.

Authors:  J Mendlewicz; M B Youdim
Journal:  Br J Psychiatry       Date:  1983-05       Impact factor: 9.319
View more
  4 in total

1.  Urinary phenylethylamine correlates positively with hypomania, and negatively with depression, paranoia, and social introversion on the MMPI.

Authors:  H W Moises; P Waldmeier; H Beckmann
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

Review 2.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

Review 3.  2-Phenylethylamine-induced changes in catecholamine receptor density: implications for antidepressant drug action.

Authors:  P R Paetsch; A J Greenshaw
Journal:  Neurochem Res       Date:  1993-09       Impact factor: 3.996

4.  Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease.

Authors:  Satoka Kasai; Toru Yoshihara; Olga Lopatina; Katsuhiko Ishihara; Haruhiro Higashida
Journal:  Front Behav Neurosci       Date:  2017-05-03       Impact factor: 3.558
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.